Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2809-2813

  Yang, Hua ^a   Zhai, Guojun ^b   Ji, Xiaoxu ^b   Xiong, Fuxia ^c   Su, Jing ^d   McNutt, Michael A ^d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

Gallbladder carcinoma (GBC); Gene polymorphism; LAPTM4B; Susceptibility

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYSOSOMAL PROTEIN TRANSMEMBRANE 4 BETA GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; FEMALE; GALLBLADDER NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS; POLYMORPHISM, GENETIC;

EID: 84867994438     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0173-4     Document Type: Article

References (22)

1. Wood R, Fraser LA, Brewster DH, et al. Epidemiology of gallbladder cancer and trends in cholecystectomy rates in Scotland, 1968-1998. Eur J Cancer. 2003;39:2080-6.
2. Diamantis I, Karamitopoulou E, Perentes E, et al. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995;22:774-9.
3. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171-90.
4. Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology. 1995;9:19-24.
5. Hui AM, Li X, Shi YZ, et al. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res. 2000;6:4272-7.
6. Hui AM, Li X, Shi YZ, et al. p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology. 2000;31:1068-72.
7. Singh MK, Chetri K, Pandey UB, et al. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19:916-21.
8. Shao G, Zhou R, Zhang Q, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22:5060-9.
9. Lee HM, Zhang H, Schulz V, et al. Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood. 2010;116:720-30.
10. Yang H, Xiong F, Wei X, et al. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 2010;294:236-44.
11. Zhou L, He X, Yu J, et al. Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepatogastroenterology. 2010;57:207-11.
12. Yang H, Xiong F, Qi R, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol. 2010;101:363-9.
13. Yang H, Xiong F, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:275-81.
14. Meng F, Yin M, Song H, et al. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010;20:745-50.
15. Meng F, Luo C, Hu Y, et al. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010;29:587-93.
16. Yin M, Xu Y, Lou G, et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011;129:629-35.
17. Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010;16:214-8.
18. Zhou L, He X, Yu J, et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 2010;199:515-21.
19. Yang Y, Yang H, McNutt MA, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 2008;20:1077-83.
20. Zhou L, He X, Cui Q, et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008;264:209-17.
21. Zhou L, He X, Chen J, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43:809-15.
22. Liu X, Xiong F, Wei X, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 2009;100:2335-40.